Dupont Capital Management Corp raised its stake in Masimo Co. (NASDAQ:MASI) by 17.0% in the 3rd quarter, Holdings Channel.com reports. The fund owned 11,972 shares of the medical equipment provider’s stock after buying an additional 1,743 shares during the quarter. Dupont Capital Management Corp’s holdings in Masimo were worth $1,781,000 at the end of the most recent reporting period.
A number of other hedge funds and other institutional investors also recently made changes to their positions in MASI. Dorsey Wright & Associates grew its stake in shares of Masimo by 0.7% in the 2nd quarter. Dorsey Wright & Associates now owns 25,700 shares of the medical equipment provider’s stock valued at $3,825,000 after buying an additional 168 shares in the last quarter. WINTON GROUP Ltd grew its stake in shares of Masimo by 60.8% in the 2nd quarter. WINTON GROUP Ltd now owns 8,899 shares of the medical equipment provider’s stock valued at $1,324,000 after buying an additional 3,366 shares in the last quarter. Handelsbanken Fonder AB bought a new stake in shares of Masimo in the 2nd quarter valued at approximately $19,867,000. NN Investment Partners Holdings N.V. grew its stake in shares of Masimo by 93.5% in the 2nd quarter. NN Investment Partners Holdings N.V. now owns 17,380 shares of the medical equipment provider’s stock valued at $2,587,000 after buying an additional 8,397 shares in the last quarter. Finally, Diversified Trust Co grew its stake in shares of Masimo by 7.0% in the 2nd quarter. Diversified Trust Co now owns 2,461 shares of the medical equipment provider’s stock valued at $366,000 after buying an additional 160 shares in the last quarter. 82.66% of the stock is owned by hedge funds and other institutional investors.
In related news, CFO Micah W. Young sold 12,087 shares of the business’s stock in a transaction that occurred on Monday, September 16th. The stock was sold at an average price of $150.02, for a total value of $1,813,291.74. Following the completion of the sale, the chief financial officer now directly owns 10,000 shares in the company, valued at approximately $1,500,200. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, Director Sanford Fitch sold 6,500 shares of the company’s stock in a transaction that occurred on Tuesday, October 1st. The stock was sold at an average price of $149.43, for a total value of $971,295.00. Following the transaction, the director now owns 50,745 shares of the company’s stock, valued at $7,582,825.35. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 34,100 shares of company stock valued at $5,138,342. Corporate insiders own 11.50% of the company’s stock.
Receive News & Ratings Via Email – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings with MarketBeat.com’s FREE daily email newsletter.
MASI has been the subject of several recent research reports. BTIG Research reissued a “hold” rating on shares of Masimo in a research note on Thursday, August 1st. BidaskClub cut Masimo from a “buy” rating to a “hold” rating in a research note on Tuesday, October 15th. Stifel Nicolaus boosted their price target on Masimo from $165.00 to $170.00 and gave the company a “buy” rating in a research note on Thursday, August 1st. ValuEngine cut Masimo from a “buy” rating to a “hold” rating in a research note on Wednesday, October 2nd. Finally, UBS Group boosted their price target on Masimo from $172.00 to $180.00 and gave the company a “buy” rating in a research note on Thursday, August 1st. Three equities research analysts have rated the stock with a hold rating and five have given a buy rating to the company’s stock. The company presently has a consensus rating of “Buy” and a consensus target price of $159.25.
MASI opened at $145.79 on Friday. The business has a 50 day moving average price of $147.44 and a 200 day moving average price of $145.35. Masimo Co. has a twelve month low of $98.23 and a twelve month high of $160.25. The firm has a market cap of $7.90 billion, a P/E ratio of 47.91, a price-to-earnings-growth ratio of 1.97 and a beta of 1.19.
Masimo (NASDAQ:MASI) last posted its earnings results on Wednesday, October 30th. The medical equipment provider reported $0.76 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $0.73 by $0.03. Masimo had a return on equity of 17.82% and a net margin of 22.15%. The firm had revenue of $229.01 million during the quarter, compared to analyst estimates of $221.92 million. During the same period in the previous year, the company earned $0.71 EPS. The company’s revenue for the quarter was up 8.8% on a year-over-year basis. On average, research analysts expect that Masimo Co. will post 3.15 EPS for the current year.
Masimo Company Profile
Masimo Corporation, a medical technology company, develops, manufactures, and markets noninvasive monitoring technologies worldwide. The company offers Masimo Signal Extraction Technology (SET) pulse oximetry with measure-through motion and low perfusion pulse oximetry monitoring to address the primary limitations of conventional pulse oximetry.
Featured Article: What are the qualifications of a portfolio manager?
Want to see what other hedge funds are holding MASI?Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Masimo Co. (NASDAQ:MASI).